Replies to post #115048 on Biotech Values

[biomaven0]

>>rida

Combo with mk2206 makes a lot of sense - when you inhibit mTor, Akt gets upregulated and much of the impact of inhibiting mTor is lost. So combo with an Akt inhibitor could be very promising.

I don't understand the combo with Notch though, although this isn't something I've ever looked at. I think Notch and Mtor are basically on the same pathway.

Bottom line though is that this shows MRK is taking this drug very seriously and are doing a very thorough job. Good thing Aria isn't still on the hook for co-development costs.

Peter

[mcbio]

biomaven any comment on today mrk starting rida with mk-0752 the notch inhibitor and mk2206?????

if nothing else mrk is moving forward for sure on combo's

Where was this disclosed? It's not in the ARIA PR and was not mentioned in the ARIA CC and I don't see anything from MRK.

Separately, from the ARIA CC today, it was disclosed that MRK has stopped the Phase 2 trials of rida in advanced prostate cancer patients and KRAS-positive NSCLC patients due to tolerability issues (mouth sores) and a less than adequate response, respectively.

On a positive note, as it pertains to ponatinib, Harvey said that ARIA does expect to ultimately expand ponatinib into AML and MM and, further down the road, solid tumors.